Ticker Hub
DNLI — AI Analysis & Sentiment
3 recent AI-generated analyses for DNLI. Sentiment and confidence insights updated continuously.
Biogen and Denali Therapeutics Provide Update on Phase 2b LUMA Study of BIIB122 (DNL151) in Early-Stage Parkinson’s Disease
Denali's Parkinson's drug failed its Phase 2b study, leading to discontinuation, which is a major pipeline setback. Despite this, the stock saw an ...
May 21, 2026Denali Therapeutics Reports First Quarter 2026 Financial Results and Business Highlights
Denali's Q1 report highlights the successful launch of its FDA-approved drug AVLAYAH and significant pipeline advancements, backed by a strong cash...
May 7, 2026Denali Therapeutics Announces U.S. FDA Approval of AVLAYAH™ (tividenofusp alfa-eknm) for Treatment of Hunter Syndrome (MPS II)
Denali Therapeutics gained FDA approval for AVLAYAH, validating its core technology and creating a new commercial revenue stream for Hunter Syndrom...
Mar 25, 2026